Trends in lipid-lowering therapies in acute coronary syndromes after Chinese new insurance policy: a real-world analysis
The PCSK9i reimburse policy adjustment was associated with increased intensive LLT for ACS in China, especially more PCSK9i prescription, which modestly correlated to higher LDL-C goal attainment rate.
Authors
- Neng Li Dai
- Bing Fan (ORCID: https://orcid.org/0000-0003-4439-6150)
- J. Qian
- Yingnan Bai (ORCID: https://orcid.org/0000-0002-8637-2301)
- Li Xu (ORCID: https://orcid.org/0000-0002-7698-9674)
- Hongyi Wu (ORCID: https://orcid.org/0000-0002-6112-9313)
- Luning Zhou (ORCID: https://orcid.org/0000-0001-5283-4769)
- Huajie Xu
- Junbo Ge
- Peng Zhang
- Shujing Wu
- Zhen Wang
- Mengmeng Yu
- Zhiyong Qi
- Xin Zhao
- Hongbo Yang
Institutions
- Sun Yat-sen University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Fudan University (CN)
- Zhongshan Hospital of Xiamen University (CN)
- Zhongshan Hospital (CN)
- The First Affiliated Hospital, Sun Yat-sen University (CN)
- YangPu Geriatric Hospital (CN)
Publication Details
- Journal
- BMC Medicine
- Published
- 2026-01-09
- DOI
- https://doi.org/10.1186/s12916-026-04616-2
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 0.00